Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Canada to Develop New Isotope Production Methods

By BiotechDaily International staff writers
Posted on 11 Mar 2013
An aging reactor and a worldwide looming shortage of medical isotopes has driven Canada to search for alternatives methods to manufacture technetium-99m (99mTc).

At the moment, Canada's only source of the isotope is the National Research Universal (NRU; Chalk River, Ontario, Canada) reactor at Chalk River Laboratories (CRL, Ontario, Canada), which produces about a third of the world's supply. But the reactor has been plagued with safety and operational problems, leading to worldwide shortages, and its license is set to expire in 2016. Consequently, Canada is investing close to USD 21 million in three projects in western Canada that have demonstrated the ability to produce the key medical isotope without a nuclear reactor.

Two of the research institutes, the national laboratory for particle and nuclear physics (TRIUMF; Vancouver, BC, Canada) and the University of Alberta (Edmonton, Canada) are using cyclotron technology to produce the isotope, while the third, Prairie Isotope Production Enterprise (PIPE; Pinawa, MB, Canada), is using a linear accelerator.

In the cyclotron process, the machine bombards a target of molybdenum-100 with high-energy protons, converting some of its atoms to molybdenum-99 (Mo-99). Then chemical processing removes technetium-99 from the target, ready for use. The PIPE technology uses an electron accelerator rather than a nuclear reactor to make the Mo-99. The electron accelerator sprays electricity onto molybdenum metal, which produces the Mo-99 radioisotope. Next, a chemical process is used to fabricate the Tc-99m.

“The Harper Government is investing in Canadian expertise to help ensure new sources of supply for medical isotopes used in diagnosing various diseases, such as cancer and heart disease,” said Joe Oliver Canada’s natural resources minister. “We are investing in the work needed to attract private sector interest and to bring new technologies to market, and to help ensure that isotope production is on a sound commercial footing.”

Tc-99m is obtained from the decay of its parent isotope Mo-99 compounds that are packed into nuclear "generators" and distributed to hospitals, where nuclear medicine specialists can draw off the Tc-99m as needed for about a week. Tc-99m is used in 80% of nuclear medicine diagnostic procedures in Canada, and about 85% of all medical imaging procedures worldwide. It is currently made in reactors in Canada, the Netherlands, Belgium, France, Australia, and South Africa.

Related Links:

National Research Universal
TRIUMF
Prairie Isotope Production Enterprise



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.